NDATOPICALCREAM
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
17
Data completeness
6/8 — Strong
ANZUPGO (delgocitinib) by Leo Pharma is janus kinase inhibitors [moa]. Approved for chronic hand eczema. First approved in 2025.
Drug data last refreshed 20h ago
Mechanism of Action
Janus Kinase Inhibitors
Pharmacologic Class:
Janus Kinase Inhibitor
Indications (1)
Clinical Trials (17)
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
Started May 2026
652 enrolled
Lichen Sclerosus
Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
Started May 2026
30 enrolled
Central Centrifugal Cicatricial AlopeciaLichen Planopilaris
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
Started Sep 2025
135 enrolled
Palmoplantar Pustulosis
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
Started Sep 2023
362 enrolled
Chronic Hand Eczema
Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema
Started Sep 2022
15 enrolled
Chronic Hand Eczema
Worked on ANZUPGO at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.